Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 15;8(10):17880-90.
eCollection 2015.

Expressions of lysophosphatidic acid receptors in the development of human ovarian carcinoma

Jinge Si  1 , Yuanyuan Su  2 , Yifeng Wang  1 , You-Liang Yan  3 , Ya-Ling Tang  4
Affiliations

Expressions of lysophosphatidic acid receptors in the development of human ovarian carcinoma

Jinge Si et al. Int J Clin Exp Med. .

Abstract

Aim: To investigate the associations between the expressions of three lysophosphatidic acid (LPA) receptors (LPA1-3) and the development of ovarian carcinoma (OC).

Method: Ovarian tissue specimens, including normal ovarian epithelium tissues, benign ovarian tumor tissues and OC tissues were collected from patients who underwent surgical resections between March 2012 and December 2014. Immunohistochemical staining was used to detect LPA receptor expressions in ovarian tissues. Reverse transcription-polymerase chain reaction and Western blotting were used to detect mRNA and protein expression of LPA receptors, respectively. Association analysis between LPA receptors protein expression and clinical pathological characteristics was conducted. The value of LPA2 and LPA3 in discriminating OC was confirmed by receiver-operator characteristic (ROC) curves analysis.

Results: The positive expression rates of LPA2 and LPA3 in OC group was obviously higher than normal control and benign groups. The LPA2 and LPA3 mRNA and protein levels in OC group were higher than in normal control and benign groups. LPA2 and LPA3 mRNA expression levels were positively correlated with LPA2 and LPA3 protein expression in OC group. ROC curve analysis revealed that LPA2 yield a specificity of 96.3% and a sensitivity of 97.9%, and LPA3 yield a specificity of 98.5% and a sensitivity of 97.9% for the detection of OC.

Conclusion: LPA2 and LPA3 were highly expressed in OC tissues, which may be involved in the development of OC. Further, LPA2 and LPA3 had higher sensitivity and specificity in distinguishing the OC from benign ovarian tumors, which could be potential diagnostic indictors in OC.

Keywords: Ovarian carcinoma; ROC curve analysis; immunohistochemical staining; lysophosphatidic acid receptors; pathological grades; pathological stages; pathological types; reverse transcription-polymerase chain reaction.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The expressions of LPA receptors in normal ovarian epithelium tissues, benign ovarian tumor tissues and epithelial ovarian carcinoma tissues by IHC staining (SP × 40). Note: A. Positive expression of LPA1 in benign ovarian tumor tissues; B. Negative expression of LPA1 in epithelial ovarian carcinoma tissues; C. Positive expression of LPA2 in epithelial ovarian carcinoma tissues; D. Negative expression of LPA2 in benign ovarian tumor tissues; E. Positive expression of LPA3 in epithelial ovarian carcinoma tissues; F. Negative expression of LPA3 in benign ovarian tumor tissues. LPA: lysophosphatidic acid; IHC staining: immunohistochemical staining.
Figure 2
Figure 2
The mRNA expression levels of LPA receptors in normal ovarian epithelium, benign ovarian tumor and epithelial ovarian carcinoma. Note: A. Electrophoresis patterns for LPA receptor mRNA expressions analyzed by RT-PCR assay. m: Marker; a, e, i: β-actin; b, f, j: LPA1; c, g, k: LPA2; d, h, l: LPA3; b-d: Epithelial ovarian carcinoma tissues (OC group); f-h: Benign ovarian tumor tissues (benign group); j-l: Normal ovarian epithelium tissues (normal control group). B. Comparison of mRNA expressions of LPA1, LPA2 and LPA3 in normal control group, benign group and OC group. LPA: lysophosphatidic acid.
Figure 3
Figure 3
The protein expressions of LPA receptors in normal ovarian epithelium, benign ovarian tumor and epithelial ovarian carcinoma. Note: A. Western blotting results of the protein expressions of LPA1, LPA2, LPA3, and β-actin among three groups. a. Epithelial ovarian carcinoma tissues (OC group); b. Benign ovarian tumor tissues (benign group); c. Normal ovarian epithelium tissues (normal control group). B. Comparison of protein expressions of LPA1, LPA2 and LPA3 in normal control group, benign group and OC group. LPA: lysophosphatidic acid.
Figure 4
Figure 4
ROC curve analysis using LPA2 and LPA3 for discriminating the ovarian carcinoma from benign ovarian tumors. Note: LPA: lysophosphatidic acid; ROC: receiver-operator characteristic curves.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Menon U. Ovarian cancer screening has no effect on disease-specific mortality. Evid Based Med. 2012;17:47–48. - PubMed
    1. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD, Team PP. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295–2303. - PubMed
    1. Orfanelli T, Jeong JM, Doulaveris G, Holcomb K, Witkin SS. Involvement of autophagy in cervical, endometrial and ovarian cancer. Int J Cancer. 2014;135:519–528. - PubMed
    1. Bordon Y. Immunotherapy: Leukadherins get a grip on inflammation. Nat Rev Immunol. 2011;11:638. - PubMed
    1. Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer. 2014;5:25–30. - PMC - PubMed

LinkOut - more resources